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Myracrodruon urundeuva (“aroeira-do-sertão”) is a species threatened with extinction due 
to anthropogenic exploitation. Phytochemical analysis of bark, branch and leaf extracts revealed 
the presence of several compounds such as flavonoids, phenols, tannins, quercetin derivatives and 
anacardic acids. Dereplication methodology was performed to tentatively identify 50 compounds 
analyzed by ultra-performance liquid chromatography coupled with an electrospray ionization 
quadrupole time-of-flight mass spectrometry operating in MSE mode (UPLC-QTOF-MSE). The 
extracts exhibited anti-tumor effect in cancer cells HCT-116 (colorectal), SF-295 (glioblastoma), 
HL-60 (leukemia), and RAJI (leukemia). Also, these results correlate with the principal component 
analysis (PCA) data that identified three distinct groups indicating, efficiently, metabolic differences 
between organs of M. urundeuva. Through discriminatory analysis of the orthogonal partial least 
squares (OPLS-DA), the variable of importance in the projection (VIP) and S-Plot, we were able to 
determine 30 potential biomarkers. The fingerprint of hydroethanolic extracts was correlated with 
the cytotoxicity assay and demonstrated a significant difference in the composition of plant extract.
Keywords: Myracrodruon urundeuva, dereplication, UPLC-MS/MS, chemometrics, cytotoxic 
activity
Introduction
Myracrodruon urundeuva Fr.All. (Anacardiaceae 
family), popularly known as “aroeira-do-sertão”, is 
a medicinal tree found in several regions of Brazil, 
especially in the caatinga.1 Currently, it is included in 
the official list of Brazilian flora species threatened 
with extinction2 in the vulnerable category due to 
indiscriminate use of the species for several purposes in 
the wood and pharmaceutical area.3
The plant raises the researchers interest due to 
anti-inflammatory properties of its extracts, notably 
associated with the presence of bioactive phenolic 
compounds such as tannins, polyphenols, ellagitannins 
and, mainly, dimeric chalcones.4 Previous studies have 
shown that the chemical properties of these substances 
may be associated with antitumor activity in lung cells 
and leukemia.5 Pharmacological studies revealed a wide 
variety of pharmacological activities including cytotoxic,6,7 
anti-inflammatory and analgesic.8 Besides, M. urundeuva 
may prevent cancer indirectly due to antioxidant and anti-
inflammatory activity of its compounds.4,8-10
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Previous studies have reported antitumor activity of 
ethanolic extracts from different sections of the plant. 
Extract dilutions yielded a half maximal inhibitory 
concentration (IC50) between 9.5-16.7 μg mL-1 against 
leukemic HL-60 and, among other types such as SF-295 
glioblastoma of IC50 17.3-36.3 μg mL-1. The activity 
of this extract was reported to occur via an apoptotic 
mechanism, which results in a reduction of cell numbers, 
cell volume, and viability in addition to internucleosomal 
DNA fragmentation.7
Pessoa et al.5 reported the action of ethanolic extracts 
of the Myracrodruon urundeuva leaf against the HL-60 
and SW-1573 lines with IC50 of 7.4 and 8.5 μg mL-1, 
respectively. Therefore, the literature shows several 
shreds of evidence of significant antitumor activity from 
M. urundeuva extracts, which motivated the study of its 
chemical composition. No previous research has been 
conducted with the identification of compounds associated 
with the biological activity of M. urundeuva extracts. The 
metabolomic study of plant samples is of great importance 
when one wants trying to associate certain bioactivity with 
the chemical composition of the extract. In this regard, 
the metabolomics focuses on the study of low molecular 
weight compounds that may be established as biomarkers11 
by means of metabolic fingerprinting and profiling.12 This 
area of study covers a set of analyses from extraction 
methods to the statistical analysis of the data in order 
to identify molecules that can function as biomarkers or 
from genome alteration.13 This is because it can be used in 
different spheres, such as metabolic fingerprint, metabolic 
profile, and metabolomics.12 The ultra-performance liquid 
chromatography (UPLC) coupled to high-resolution mass 
spectrometry (HRMS) has the ability and sensitivity to 
provide a high-resolution mass spectrum for a complex 
matrix as a plant extract. Therefore, it is widely used in 
metabolomics studies involving identification of substances 
from high complexity extracts.14-16
Ultra-performance liquid chromatography coupled with 
an electrospray ionization quadrupole time-of-flight mass 
spectrometry operating in MSE mode (UPLC-QTOF-MSE) 
allied to chemometric analysis is very useful for the 
identification of compounds by comparison of different 
matrices. Further analyses as principal component analysis 
(PCA) and orthogonal projections to latent structures 
discriminant analysis (OPLS-DA) identify groups that 
differ from each other, as well as presenting the responsible 
components that cause these differences, which are 
recognized as discriminant.17 Thus, these analyses help 
to provide information about compounds that could be 
used as diagnostic to each sample type, therefore potential 
biomarkers.
Present work aimed to explore differences in metabolic 
fingerprints of M. urundeuva leaves, branches, and 
bark ethanolic extracts by using UPLC-QTOF-MSE and 
multivariate modeling (PCA and OPLS-DA) in order to 
search associations between chemical composition and 
cytotoxic effect.
Experimental
Plant material
Samples of leaf, bark and branch from M. urundeuva 
were collected from naturally occurring young plants 
from the Embrapa semi-arid experimental field, close to 
the border between the municipalities of Petrolina and 
Lagoa Grande (Pernambuco State, Brazil, 09°04’16.4”S, 
40°19’5.37”W) on August 24, 2016, between 9 and 
10 o’clock in the morning. The voucher specimens have 
been deposited in the Herbarium with number HTSA4978. 
Samples of leaves, bark, and branches were collected 
in biological quintuplets (in five different trees) taking 
into account the four quadrants of the tree, in the north, 
south, east and west directions. The four quadrants were 
assembled in single samples for each section of the plant. 
At the time of collection, the liquid nitrogen cooling process 
was performed at –80 °C. After that, the material was dried 
in a forced circulation oven at 40 °C for 168 h (one week). 
Prior to extraction, the samples were ground in a knife mill 
and stored in a plastic bag at room temperature.
Chemicals
The solvents used were from LiChrosolv® of the Sigma-
Aldrich Chemical Company (St. Louis, MO, USA). In all 
methods, high purity Milli-Q water (Billerica, MA, USA) 
was used. The standards for chlorogenic acid and corilagin 
were obtained from Sigma-Aldrich Chemical Company 
(St. Louis, MO, USA) and urundeuvine A and B were 
previously isolated by our laboratory.
Sample preparation
The method used was adapted for the preparation of 
extracts by liquid-liquid partition.18,19 Leaves, branches, 
and bark (50 mg) were added in Falcon (15 mL) tube and 
extracted with 4 mL hexane, at room temperature, for 
20 min in ultrasound batch. Afterward, 4 mL of EtOH:H2O 
(7:3) solution was added. The samples were extracted again 
with hexane, and the hydroethanolic partition was collected 
to yield the corresponding EtOH extract. Finally, a 1 mL 
aliquot of the lower (hydroethanolic) phase was filtered 
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(0.20 μm polytetrafluoroethylene (PTFE)), collected in 
flasks and stored at –80 °C until further UPLC analysis.
Chromatographic conditions
The analysis was performed using an Acquity UPLC 
(Waters) system, coupled with a quadrupole/TOF 
(Waters) system. A Waters Acquity UPLC BEH column 
(150 × 2.1 mm, 1.7 μm) was used, with the column 
temperature set at 40 °C. The binary gradient elution 
system consisted of 0.1% formic acid in water (A) and 
0.1% formic acid in acetonitrile (B). The UPLC elution 
conditions were optimized as follows: linear gradient 
from 2 to 95% B (0-15 min), 100% B (15-17 min), 2% B 
(17.01 min), 2% (17.02-19.01 min), a flow of 0.4 mL min-1, 
and a sample injection volume of 5 μL.
Mass spectrometry conditions
The chemical profiling of M. urundeuva leaves, 
branches, and bark extracts was performed by coupling 
the Waters Acquity UPLC system to the QTOF mass 
spectrometer (Waters, Milford, MA, USA) with the 
electrospray ionization interface (ESI) in positive and 
negative ionization modes. The ESI+ and ESI– data was 
acquired in the range of 110-1180 Da, with a fixed source 
temperature of 120 °C, and a desolvation temperature 
of 350 °C. A desolvation gas flow of 350 L h-1 was used 
for the ESI+ mode and the 500 L h-1 for the ESI− mode. 
The capillary voltage was 3 kV. Leucine enkephalin 
was used as a lock mass. The MS model used was 
Xevo G2-XS QTOF. The spectrometer operated with MSE 
centroid programming using a tension ramp from 20 to 
40 eV. The instrument was controlled by MassLynx 4.1 
software (Waters Corporation).
Chemometric data analysis
The UPLC-MS data of all samples were analyzed 
using the MarkerLynx XS software20 to identify potential 
discriminatory chemical markers in different extracts. 
For data collection, the method parameters were set as 
retention time (tR) range, 0.88-17.0 min, and mass range 
of 110-1180 Da. For data analysis, a list composed of 
the identities of the detected peaks was generated using 
retention time (tR)-mass data (m/z) pairs as the identifier 
for each peak. An arbitrary ID was assigned to each of 
this tR-m/z pairs based on their order of elution from the 
UPLC system. The ion intensity for each detected peak was 
normalized against the sum of the peak intensities within 
that sample. Ion identification was based on the tR and m/z 
values. The resulting three-dimensional data comprising 
peak number (tR-m/z pair), sample name, and ion intensity 
were analyzed by PCA and OPLS-DA using MarkerLynx.20
Cytotoxicity of leaf, bark, and branch samples from 
M. urundeuva
Cell lines and cultures
Cytotoxicity tests were performed against HCT-116 
and SW-620 (colorectal), SF-295 (glioblastoma), HL-60 
and RAJI (leukemia), PC3 (prostate) and L929 (murine 
fibroblast) cell lines, which were obtained from the 
National Cancer Institute (Washington, DC, USA). All 
cells were cultured in Roswell Park Memorial Institute 
(RPMI) 1640, except for L929, which was cultivated 
in Dulbecco’s Modified Eagle Medium (DMEM). Both 
mediums were supplemented with 10% fetal bovine serum 
(FBS) and 1% antibiotics (100 U mL-1 penicillin and 
100 μg mL-1 streptomycin) at 37 °C with 5% CO2. The 
L929 cell line was used to evaluate the selectivity of the 
extracts and these assays, the anticancer drug doxorubicin 
was used as positive control.
Determination of cytotoxicity - MTT assay
The determination of cytotoxicity was performed by 
the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazoliumbromide) colorimetric method.21 The 
samples were tested at 100 μg mL-1 in six tumor cell lines 
for initial screening; the IC50 concentration was determined 
for those samples that showed positive results (growth 
inhibition > 75%) in at least three cell lines. The cells were 
plated in 96-well plates at the following concentrations: 
HCT-116 / SW-620: 0.7 × 105 cells mL-1; SF-295 / PC3 / 
L929: 0.1 × 106 cells mL-1; HL-60: 3 × 106 cells mL-1; 
RAJI: 4 × 105 cells mL-1. The cells were treated with the 
extracts for 72 h. At the end of the treatment, the plates were 
centrifuged, and the supernatant removed. Then, 150 μL 
of MTT solution (0.5 μg mL-1) was added and incubated 
for 3 h. After incubation, the MTT solution was removed, 
and the precipitated formazan was dissolved with 150 μL 
of dimethyl sulfoxide (DMSO). The absorbances were read 
using a plate spectrophotometer (Multimode Detector, DTX 
880, Beckman Coulter) at 595 nm.
Statistical analysis of data activity
All experiments were performed in duplicate and 
repeated three times. For all samples, the selectivity 
index (SI) was calculated. The calculation of this index 
corresponds to the division between the IC50 value of 
each test compound in the L929 non-tumor cell line and 
the IC50 value of each compound in the tumor cell line 
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(SI = IC50L929 / IC50neoplastic cells).22 The experiments 
were analyzed according to the mean ± standard deviation 
(SD) of the percentage of cell growth inhibition using the 
GraphPad Prism software.23
Results and Discussion
Chemical profile by UPLC-QTOF-MSE
The ethanolic extracts of the three sections of 
M. urundeuva were obtained from the methodology 
described in “Sample preparation” sub-section. The 
extracts were analyzed by UPLC-QTOF-MSE following the 
parameters described in “Chromatographic conditions” and 
“Mass spectrometry conditions” sub-sections only in the 
negative mode. In all, about 50 compounds were tentatively 
identified, covering the three sections of the species studied 
using MS and MS/MS from the chromatographic analysis 
(Figure 1). These results were compared to the data reported 
in the literature (chemotaxonomic) referring to the family 
(Anacardiaceae) and the genus (Myracrodruon) because 
there are few reports concerning the species. We used 
databases such as PubChem, ChemSpider, and Scifinder 
to support the results.
A wide range of phenolic compounds was identified, 
mainly derived from flavonoids and tannins. The predominant 
compounds in leaves were corilagin, firstly reported to the 
species, as well as geraniinic acid, and compounds well 
known in the literature as quercetin, gallic acids, and 
anacardic acids derivatives. The ethanolic extract of branches 
presented predominantly chlorogenic acid, quinic acid 
derivatives and the dimeric chalcones, urundeuvines A and 
B. The bark presented mostly catechin derivatives, in addition 
to the compounds contained in the branch.
A fragmentation study of the possible biomarkers 
tentatively identified was performed, presented below. The 
remaining substances have been tentatively identified and 
are presented in Table S1 and Figure S1 (Supplementary 
Information section).
Hydrolysable tannins
Peaks 13, 14 and 19 showed a precursor ion with 
[M − H]− at m/z 951.0764, 633.0710 and 953.0887, 
respectively. Peak 13 showed fragments in 933.0729 
[M − H − H2O]− and 300.9977 [M − H − 633 − H2O]− 
indicating losses of a water and corilagin unit with 
water. This compound was identified as geraniin from 
the literature data with a molecular mass of C41H28O27.24 
Peak 14 presented MS/MS fragmentation pattern with 
loss of galloyl unit and water that showed fragment 
in 463.0564 [M − H − 152 − H2O]− and fragment in 
300.9953 [M − H − 152 − 180]− that corresponds to the 
loss of a galloyl unit with a hexose. This compound was 
identified as corilagin according to information previously 
reported in the literature,24 with a molecular formula of 
C27H22O18. Corilagin identification was confirmed by the 
comparison with molecular ion and fragmentation pattern 
of an analytical standard sample presented in Figure S2 
(Supplementary Information section). Peak 19 showed 
similar fragments of the compound 13 at m/z 300.9953 
[M − H − 3 × 152 − 180 − H2O]− and m/z 169.0121 as 
deprotonated gallic acid. This compound was identified 
as geraniinic acid with a molecular formula of C41H30O27. 
Figure 1. Typical base peak intensity (BPI) chromatograms showing the profiles of leaf, branch, and bark of M. urundeuva in the negative ionization mode.
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The fragmentation pattern was very similar, and they 
are derived from the ellagitannin common in the genus 
Phyllanthus.25 These compounds are being reported for 
the first time to the Anacardiaceae family.
Flavonols
Peaks 24, 26, 27, 33 and 46 were identified as quercetin 
derivatives. Peak 24 presented precursor ion [M − H]− at 
m/z 497.1338 (C22H26O13). It is an unidentified compound 
but may be considered quercetin derivative because it 
presents a characteristic fragment ion at m/z 301. Peak 
26 presented precursor ion [M − H]− at m/z 463.0867 
(C21H20O12). This compound presented fragments in 301 
[M − H − 162]− indicating loss of hexoside unit. The 
identification of quercetin-3-O-galactoside was based 
on the work of Erşan et al.26 of Pistacia vera L., which 
belongs to Anacardiaceae family. Peak 27 was identified 
as quercetin-3-O-glucuronide similarly to the above 
compounds with precursor ion [M − H]− at m/z 477.0648 
(C21H18O13). The main fragment at m/z 301 [M − H − 176]− 
confirms the quercetin derivatives. Peak 33 presented 
precursor ion [M − H]− at m/z 433.0777 (C20H18O11) and 
was identified as quercetin-3-O-arabinopyranoside. This 
determination was performed by comparison to the work 
of Schieber et al.27 while was identified these compounds in 
the respective elution order. The main fragment at m/z 301 
[M − H − 132]− confirms the quercetin derivatives by the 
loss of pentoside unit. Peak 46 presented the deprotonated 
ion [M − H]− at m/z 599.0995 (C28H24O15) with fragment 
MS/MS at m/z 301 [M − H − 298]− referring to the loss of 
one unit of raminoside-gallate, characteristic of quercitrin 
2-O-galate, previously identified by Abu-Reidah et al.28
Flavanols
Peaks 9 and 15 were identified as gallocatechin 
derivatives. All gallocatechin derivatives have a 125 Da 
fragment.29 This fragmentation is shown in Figure 2 by 
the formation of free phenol and the non-formation of a 
fragment of the gallic acid, indicating the gallocatechin 
and epigallocatechin compounds. This proposal was 
based on Miketova et al.29 Peak 9 presented precursor 
ion [M − H]− at m/z 305.0653 (C15H14O7) which, 
according to the previous reference, was identified as 
gallocatechin/epigallocatechin. Identification of the 
correct stereochemistry is not possible only by the 
fragmentation pattern. The comparison with an analytical 
standard as well as isolation of the compound and 
analysis by other techniques would be necessary. Peak 15 
presented precursor ion [M − H]− at m/z 457.0768. The 
fragmentation of peak 15 differs from 9 by the presence 
of the fragments at m/z 305.0664 [M − H − 152]− and 
169.0125 [M − H − 288]− indicating the loss of a galloyl 
unit with the formation of the epigallocatechin unit and 
gallic acid deprotonated unit, respectively. The formation 
of this compound fragments is presented in Figure 2.
Other compounds
Peak 3 presented precursor ion [M − H]− 133.0129 
(C14H8O). In the MS/MS spectrum was at m/z 115.0042 
Figure 2. Proposed fragmentation of epigallocatechin 3-O-gallate, collision energy ramp 20-40 eV (adapted from reference 29).
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[M − H − H2O]−. Based on Abu-Reidah et al.28 work, it was 
identified as malic acid.28
Peak 5 demonstrated in its first-order spectrum the 
molecular ion m/z [M − H]− at 191.0192 (C6H8O7). This 
compound presented fragment in 111.0079 Da and it was 
possible to identify as citric acid as suggested by Lafontaine 
and co-workers.30
Peaks 10, 20, 25, 30, 35, 36, 42, 45 and 50 presented 
precursor ion [M − H]− at m/z 483.0813, 785.0815, 497.1295, 
939.1104, 1091.1266, 341.0647, 629.1295, 603.1172 
and 447.0757, respectively. All compounds showed the 
presence of the same fragment in 169 Da corresponding 
to deprotonated gallic acid. Peaks 10, 30 and 35 presented 
fragments with loss of 152 Da each that correspond to 
galloyl unit. The precursor ions of the peaks 30 and 35 were 
reported in the literature to the methanolic extracts leaf of 
M. urundeuva1 as a series of galloylglucose. Based on other 
reports,26,28 these compounds were identified as pentagalloyl 
hexoside and hexagalloyl hexoside, respectively.
Peak 12 showed a precursor ion [M − H]− at 
m/z 353.0861 (C16H18O9), that was identified as chlorogenic 
acid. To confirm the identification, the mass spectrum 
(MS/MS) of the analytical standard was compared with 
that of the extract, where similarity in retention time 
was observed, and the same fragment at m/z 191.0529 
[M − H − 162]−.
Peak 16 exhibited deprotonated ion [M − H]− 337.0910 
(C16H18O8). The MS/MS spectrum presented as the base 
peak the ion fragment at m/z 191.0525, corresponding to 
the deprotonated quinic acid. The characteristic fragment 
ion at m/z 163.0423 corresponds, undoubtedly, to coumaric 
acid. According to Plazonić et al.,31 the compound was 
tentatively identified as 5-p-courmaroil quinic acid presented 
in Figure S3 (Supplementary Information section).
Peaks 29 and 51 showed precursor ions [M − H]− 
at m/z 467.0902 (C31H16O5) and 193.0869 (C11H14O3), 
respectively. Despite a broad review of the literature, these 
compounds remained unidentified.
Peaks 55 and 56 were identified as urundeuvine isomers 
from the comparison with analytical standards. Peaks 55 
and 56 presented precursor ions [M − H]− at m/z 525.1268 
and 525.1212 (C30H22O9). Both peaks have the same 
fragmentation pattern corresponding to urundeuvine A 
analytical standard as can be seen in the MS/MS spectrum 
(Figure 4).
In addition, the assignment was corroborated with 
a comparison between the retention times in the extract 
and in the analytical standard that was 6.24 and 6.63 min; 
and 6.24 and 6.69 min, respectively. Therefore, these 
compounds were identified as urundeuvines A isomers II 
and III. Similarly, MS/MS spectra and retention time 
based the identification of peak 57 on the comparison of 
extract with urundeuvine B analytical standard. This peak 
presented precursor ion at m/z 523.1036 [M − H]− and 
retention time of 6.78 min. Based on this information, the 
compounds were identified as urundeuvines B isomer II.
Peaks 60 and 62 were identified as anacardic acid 
(17:3) and (17:2),26 respectively presenting at m/z 369.2400 
(C24H34O3) and 371.2587 (C24H36O3). All of them presented 
a loss of one molecule of CO2 equivalent to 44 Da in 
MS/MS, common in this type of molecule, giving the 
fragments at m/z 325.2519 and 327.2703.26,32
Chemometric analysis
The main objective of using PCA analysis is to 
transform large amounts of complex analytical data into 
easily understood data.33 The analysis allowed to observe 
Figure 3. Spectrum in negative ion mode (ESI-MS/MS) of chlorogenic acid in the sample (a) and analytical standard (b).
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more clearly the metabolic differences between the different 
M. urundeuva samples: leaf, branch, and bark. The PCA 
plot (Figure 5) represented 83.34% of the total variance 
(R2X [1] = 0.5959 and R2X [2] = 0.2375), using the Pareto 
scale. The groups formed to indicate that the secondary 
metabolites of the leaf, branch, and bark differ significantly. 
The first major component (PC1) represents the largest 
variation in the dataset; the branch and bark samples are 
on the PC1 positive side, while the leaf samples are on 
the negative side. The second main component (PC2) 
corresponds to the maximum amount of variance not 
explained by PC1, in which case the branch is positive for 
PC2 and leaf, and bark is negative. Therefore, according to 
the PCA data, it is evident that the three parts of the plant 
differ from the respective chemical profiles.
After analysis of principal components for all samples, 
OPLS-DA was performed among the three groups (leaf-
bark, leaf-branch, and bark-branch). It was possible 
to verify clearly the formation of distinct groups, also 
observed in the PCA, demonstrating the dissimilarity 
between leaves, branches, and barks. In addition, in the 
OPLS-DA, the intra-group variation can be observed, 
that is, how much the samples from the same tissues 
may differ from each other, and in this case, a greater 
homogeneity occurred in the leaf samples compared to 
bark and branch samples as shown in the OPLS-DA graphs 
(Figure 6). The good quality of the model is expressed 
in R2Y (explained variance) and Q2 (predicted variance), 
where the values must be above 0.5 and the closer to 1 the 
more reliable.34
For the analysis, R2Y and Q2 ranged from 0.98 to 0.99, 
indicating that the results are highly reliable. In order to 
identify the metabolites that have the greatest contribution 
to the distinction between the parts of the plant, other 
statistical tools derived from the OPLS-DA were used: 
VIP (variable of importance in projection) and S-Plot. By 
employing VIP, it is possible to predict which are the most 
significant variables for the selection of biomarkers, in 
general, VIP > 1 is considered statistically significant.35 In 
the present study, VIP > 1 and p < 0.05 were used. S-Plot 
highlights the discriminant variables, that is, those that 
move away from the common axis between the two groups 
compared. Figure 7 presents the VIP and S-Plot graphs 
for the leaf-bark group. The complete data containing all 
Figure 4. Spectrum in negative ion mode (ESI-MS/MS) of urundeuvine A in the samples (a) bark and (b) branch; and analytical standard (c).
Figure 5. PCA analysis of leaf, branch and bark extracts of M. urundeuva (negative mode, tR range: 0.88-17.0 min).
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Figure 6. OPLS-DA analysis of groups: (a) leaf-branch; (b) leaf-bark; (c) bark-branch of M. urundeuva (negative mode, tR range: 0.88-17.0 min).
Figure 7. VIP of leaf samples (a), bark (b), S-Plot of leaf samples (c) and bark (d) and bar graph of leaf samples (e) and bark (f) of M. urundeuva.
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other comparisons made through the S-Plot and bar charts 
are presented in the Figures S4 and S5 (Supplementary 
Information section).
After the combination of OPLS-DA, VIP and S-Plot it 
was possible to tentatively identify the possible biomarkers 
(Table 1) that may be associated with the highest cytotoxic 
activity presented in all biomarkers of leaf, bark and branch 
extracts.
Cytotoxic activity
The screening tests (100 μg mL-1) showed growth 
Table 1. Biomarkers present in leaf, branch and bark ethanolic extracts of M. urundeuva by UPLC-QTOF-MSE
Peak tRa / min
MSb 
[M − H]− MS/MS
Molecular 
formula Tentative identification
M. urundeuva
VIPc p-valued
Leaves Branch Bark
3 0.96 133.0129 115.0042 C14H8O malic acid + 3.67 1.09 × 10-8
5 0.98 191.0192 111.0079 C6H8O7 citric acid + 5.00 2.55 × 10-5
9 2.24 305.0653 125.0232 C15H14O7 gallocatechin / 
epigallocatechin
+ 3.67 5.28 × 10-10
10 2.77 483.0813 331.0816; 169.0153 C20H20O14 digalloyl hexoside + 4.59 1.34 × 10-9
12 3.00 353.0896 191.0493; 127.0390 C16H18O9 chlorogenic acide + ++ 10.52f 2.55 × 10-7f
13 3.26 951.0764 933.0729; 300.9977 C41H28O27 geraniing + 3.87 2.54 × 10-8
14 3.30 633.0744 463.0564; 300.9948 C27H22O18 corilagineg + 6.23 6.28 × 10-6
15 3.48 457.0768 305.0664; 169.0125; 
125.0248
C22H18O11 epigallocatechin-3-O-gallateg + 3.77 1.66 × 10-10
16 3.50 337.0910 191.0525; 163.0423; 
93.0346
C16H18O8 5-p-courmaroil quinic acidg + 5.34 6.95 × 10-12
19 3.80 953.0887 300.9953; 169.0121 C41H30O27 geraniinic acidg + 5.96 3.56 × 10-7
20 3.87 785.0815 300.9965; 169.0135 C34H26O22 n.ih + 6.34 1.69 × 10-11
24 4.08 497.1338 301.0029 C22H26O13 n.ih + 3.18 9.02 × 10-9
25 4.11 497.1295 313.0569; 217.0141; 
169.0131
C22H25O13 n.ih + 4.81 4.15 × 10-12
26 4.20 463.0881 301.0127 C21H20O12 quercetin 3-O-glucoside 
(isoquercitrin)g
+ 3.77 2.46 × 10-10
27 4.21 477.0648 301.0137; 151.0047 C21H18O13 quercetin -O-glucuronideg + 4.00 1.06 × 10-9
29 4.24 467.0902 357.0596; 217.0108 C31H16O5 gallic acid derivative I + 7.70 4.34 × 10-9
30 4.27 939.1104 769.0933; 617.0834; 
169.0125
C41H32O26 pentagalloyl hexoside + 3.19 7.69 × 10-8
33 4.49 433.0777 301.0091; 300. 0276 C20H18O11 quercetin 3-O- 
arabinopyranosideg
+ 3.32 1.28 × 10-9
35 4.58 1091.1266 939.1158; 769.0972 C48H36O30 hexagalloyl hexoside + 4.11 4.1 × 10-7
36 4.74 341.0647 217.0136; 189.0191; 
169.0123
C18H14O7 n.ih + 6.72 3.35 × 10-12
42 5.18 629.1295 519.0919; 467.1021; 
169.0126
C33H26O13 n.ih + 4.22 5.50 × 10-9
45 5.34 603.1172 341.0698; 323.0532; 
169.0111
C31H24O13 n.ih + 3.35 3.21 × 10-8
46 5.44 599.0995 301.0322 C28H24O15 quercitrin O-galate isomer Ig + 4.79 5.02 × 10-11
50 5.59 447.0757 295.0283; 169.0137 C24H16O9 n.ih + 3.41 3.35 × 10-12
51 5.79 193.0869 178.0597; 163.0395 C11H14O3 n.ih + 3.12 9.04 × 10-9
55 6.24 525.1195 389.1032; 371.0961; 
135.0076
C30H22O9 urundeuvine Ae + ++ 4.74f 5.59 × 10-8f
56 6.63 525.1180 389.1053; 371.0939; 
135.0079
C30H22O9 urundeuvine A isomere + ++ 4.79f 1.18 × 10-12f
57 6.78 523.1036 521.0576; 387.0816; 
371.0969; 135.0080
C30H20O9 urundeuvine Be + 3.89 1.3 × 10-8
60 15.38 369.2400 325.2519; 255.2318; 
183.0120; 133.0716
C24H34O3 anacardic acid (17:3)g + + 1.89 0.0324
62 16.05 371.2587 327.2703 C24H36O3 anacardic acid (17:2)g + + 4.10 1.94 × 10-5
aRetention time; bmass spectrometry; cvariable of importance in projection; dprobability value; ecompounds that were compared with an analytical standard; 
fVIP and p-value values of the part of the plant that has the highest relative concentration of the compound tentatively identified; gcompounds reported for 
the first time, in Myracrodruon urundeuva; hnot identified. +: lower relative concentration; ++: highest relative concentration.
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inhibition above 70% in all cell lines exposed to ethanolic 
bark extracts. The leaf extracts were toxic only to leukemia 
(HL-60) cells. Table 2 shows the results of the cytotoxicity 
assays.
After initial screening, IC50 tests were performed with 
the bark and leaf extracts. The extracts showed higher 
cytotoxic potential against the leukemic cell line with IC50 
ranging from 17.46 (bark) to 18.55 μg mL-1 (leaf) (Table 3).
Other studies show in vitro cytotoxic effects of 
plant ethanolic extracts. IC50 of 38.1 μg mL-1 was found 
after treatment of leukemic cells with ethanolic extract 
of M. urundeuva seeds.7 The authors showed DNA 
fragmentation and mitochondrial depolarization caused 
by seed extracts.
Studies on the inhibition of tumor cells growth under 
the effect of the ethanolic extract of M. urundeuva were 
carried out.5 IC50 values for this study were 7.4 μg mL-1 
against HL-60 and 8.5 μg mL-1 against SW-1573. Bark 
ethanolic extract, for example, presented 95.6% growth 
inhibition for the breast, colon, and glioblastoma lines.6
Viana et al.4 demonstrated that hydroethanolic 
extract of M. urundeuva bark exerts anti-inflammatory 
and analgesic effects related to chalcones. The extracts 
have antioxidant properties attributed to flavonoids.36 
Souza et al.8 demonstrated the anti-inflammatory and 
protective effects against gastric ulcer in mice or rat after 
treatment with fraction rich in tannins extracted from the 
“aroeira” using ethyl acetate as the solvent.
The selectivity index (SI) of each sample was evaluated. 
The SI measures how much a compound is active against 
tumor cells without causing damage to non-tumor ones, and 
it is interesting when it presents values greater than 2.0.37 
In the cell lines tested the leaf extract showed selectivity 
to the HL-60 line with an index higher than 2. This result 
can be correlated by the possible biomarkers, tentatively 
identified via chemometric analysis, present in the leaf, such 
as corilagin, geraniin, geraniinic acid, quercetin derivatives, 
among others.
Corilagin, a compound well described in the literature, 
presents a variety of pharmacological effects, such as 
anti-tumor,38 anti-inflammatory,39 antioxidant,40 and 
hepatoprotective.41 Also, the literature reports good 
antitumor activity along with low toxicity to healthy cells 
and tissues, making corilagin a promising anticancer 
lead molecule.42 The geranin, another possible adjuvant 
compound, is known to exert antitumor,43 antibacterial,44 
antioxidant45 and antiviral activities.46,47 It has already been 
reported in the literature48-50 that quercetin and its derivatives 
are well known for their antioxidant, antihistaminic and 
anti-inflammatory properties. The quercetin is being 
considered a promising new chemotherapeutic agent, and 
several studies are underway to explore molecules derived 
from quercetin for cancer-directed chemotherapy.51 In 
addition, there may be other substances, as well as their 
synergistic compounds, that play significant roles in the 
reported bioactivity but were not identified in the present 
work due to limitations of the technique chosen.
The bark showed very promising results. The SI was 
Table 3. IC50 values with a 95% confidence interval of M. urundeuva extracts in tumor and non-tumoral cell lines
IC50a (interval) / (μg mL-1)
Sample SF-295 (glioblastoma)
PC3 
(prostate)
HL-60  
(leukemia)
RAJI  
(leukemia)
HCT-116  
(colorectal)
SW-620  
(colorectal)
L929 
(murine fibroblast)
Bark 38.86 (31.03-48.67) > 100
17.46 
(16.29-18.70)
65.73 
(56.77-76.11)
32.50 
(29.44-35.87)
40.68 
(30.64-54.00) > 100
Leaf 72.61 (55.80-94.49) > 100
18.55 
(14.80-23.26)
55.42 
(44.49-69.04)
55.60 
(47.24-65.45) > 100
55.42 
(47.06-65.26)
Doxorubicinb 0.25 (0.22-0.28)
0.44 
(0.34-0.54)
0.01 
(0.005-0.01)
0.46 
0.45-0.47
0.11 
(0.08-0.14)
0.03 
(0.02-0.05)
0.99 
(0.92-1.08)
aHalf maximal inhibitory concentration (IC50) values with a 95% confidence interval obtained by non-linear regression from three independent experiments 
performed in duplicate on six tumor lines and one non-tumor line; bdoxorubicin was used as a positive control.
Table 2. Average cell growth inhibition (GI) of M. urundeuva extracts at 100 μg mL-1
Extract HL-60a / % SDb / % HCT-116c / % SDb / % SF-295d / % SDb / % RAJIa / % SDb / %
Leaves 86.14 4.62 69.48 4.23 64.93 3.24 41.84 3.38
Branch 41.98 4.94 − − 10.52 5.47 − −
Bark 88.56 1.99 80.47 2.46 83.41 1.87 77.56 0.70
aLeukemia; bstandard deviation; ccolorectal; dglioblastoma. Results are expressed as mean percent cell growth inhibition (IC) and standard deviation for 
two independent experiments in triplicate.
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higher than 2 for all cell lines tested except for prostate 
(PC3) and leukemia (RAJI) (Table S2, Supplementary 
Information section). Eventually, in the extract, it is possible 
to highlight the discriminant biomarkers belonging to bark 
that may be related to the cytotoxic activity presented, 
such as urundeuvine A, galloy derivatives, catechins, and 
phenolic acids. Bandeira et al.52 had successfully isolated 
dimeric chalcones: urundeuvine A, B, C and matosin from 
the internal bark of M. urundeuva, and Souza et al.8 had 
demonstrated antimicrobial and anti-inflammatory activity 
for M. urundeuva. The literature also has evidence for the 
antitumor activity being promoted by specific classes of 
flavonoids such as chalcones, flavonones, and flavones. 
Many derivatives of these classes showed significant 
activities against some tumoral cell lines such as human 
colon, breast, and kidneys.53 Different polyphenols from 
“aroeira-vermelha” (Schinus terebinthifolius Raddi) induced 
cell death of human prostate carcinoma and were considered 
capable of modulating cell proliferation according to the test 
concentration.53 The use of catechins has shown inhibition 
of prostate and colon cancer.54,55 The combination of 
classical chemotherapy with nutrients and especially with 
polyphenols may decrease the pressure and the adverse 
effects of the antineoplastic drug.56 Therefore, three of the 
polyphenols present in the bark of the “aroeira” tree are 
promising compounds for isolation or synthesis into the 
development of phytopharmaceutical products from natural 
extracts. Chemical investigations of this extract can be a 
promising strategy for the discovery of phytotherapeutic 
agents. Also, the chemical profile comparison of bark and 
branch extracts revealed compounds that may be important 
for their biological activity.
Conclusions
From a simple and rapid extraction method, it was 
possible to trace the chemical profile of the three plant 
organs of M. urundeuva as leaf, branch and bark using the 
analytical technique UPLC-QTOF-MSE, which allowed 
the tentative identification of 50 compounds which covered 
several classes of compounds as flavonoids, flavanoids, 
hydrolysable tannins and anacardic acid. From the 
multivariate data analyses presented, it was possible to have 
information about the metabolic differences between the 
extracts compared. Such an association has been significant 
in the discussion of observed activities because the extracts 
obtained different responses against the tested lines.
The bark and leaf extract showed high toxicity and low 
IC50 values against the HL-60 (leukemia), HCT-116 (human 
colon) and RAJI (leukemia) cell lines compared to the 
branch. The higher relative concentration of compounds 
derived from quercetin, galloy derivatives, and phenolic 
acids present in these extracts may contribute to the 
understanding of the observed high cytotoxic activity. 
Some of the compounds identified, such as quercetin 
derivatives, corilagin, and chlorogenic acid, already has 
activities recognized as anti-tumor, antioxidants, and 
anti-inflammatory, among others, which may explain the 
promising activities observed here compared to literature.
Besides, through the statistical analysis, it was possible 
to observe the separation of the groups concerning each 
part of the plant and the identification of the 30 possible 
biomarkers. Therefore, this metabolic study notes the 
importance and value of the M. urundeuva plant as a 
possible source of secondary metabolites that are likely to 
act to inhibit certain types of cancer cells.
Supplementary Information
Table of tentative identification of the secondary 
metabolites present in the ethanolic extracts of leaf, bark, 
and branches of M. urundeuva; values of IC50 (non-tumor 
cells) / IC50 (tumor cell) selectivity index in tumor lines; 
spectrum in negative ion mode (ESI-MS/MS) of corilagin 
and 5-p-courmaroil quinic acid; S-Plot of leaf samples, 
branch, bar graph of leaf samples and branch; S-Plot of 
bark samples, branch and bar graph of bark samples and 
branch of M. urundeuva are available free of charge at 
http://jbcs.sbq.org.br as PDF file.
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